How often do you monitor labs in patients taking methotrexate?

Lab monitoring for patients taking MTX should be based on a few key principles. It should be done at least on a quarterly basis, ie every 3 months, if the patient is prescribed a stable dose and does not belong to one of the higher risk categories for the development of toxicities. These risk factors include: obesity, diabetes, moderate alcohol consumption, renal impairment and prior issues with cytopenias, In these situations, lab testing may need to be stepped up to every 8-12 weeks.

It is important to note that in many cases of LFT elevations with MTX, the rise is moderate (1.5 -3x ULN) and it may be transient, lasting days to weeks. If testing is very sporadic, the rise may be missed altogether.

A challenge we all face when using e-pres...

@Dr. First Last: I agree, especially when you look at the Nakafero data.

I am from the same school as @Dr. First Last and others in my generation; we were taught to check labs q 4-12 weeks. These recommendations for timing of labs were not based upon any sound medical evidence, other than noting that doctors who did not monitor labs well would, unfortunately, end up having some patients with cirrhosis or severe cytopenias.

Following MTX patients q 4-12 weeks for over 30 years I have found:

• The vast majority of my patients never, or rarely, have any significant abnormalities. During the past decade, I have often wondered, "Am I making this low-risk patient, who is in remission on MTX, come in too often?"
• When I do see complications, it is a...

Many of our patients are on methotrexate for decades without events or laboratory abnormalities. If a patient has had stable labs every 2 to 3 months for the first year (e.g. are low risk for toxicity), I stretch out the intervals to every six months. I would never do this in a patient with steatosis, diabetes, significant daily alcohol intake or someone with previously abnormal labs. This has been examined quantitatively in MS (Nakafero et al., PMID 37253479) and discussed (Ranganathan, PMID 37253486) and is the most recent study on this topic.

Can those who have answered above comment on how much they "tolerate" elevated LFTs? Does any elevation in LFTs make you stop MTX, how many "transient elevations" do you tolerate before stopping MTX? In a q 3 month MTX monitoring scenario, what percentage of transient elevations would have you stop MTX? Thanks!